【摘 要】
：
目的: Gefitinib has come to be the most widely used epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in treatment of advanced non-small cell lung cancer (NSCLC) in Asian patients.Co
【机 构】
：
310006 杭州市第一人民医院集团杭州市肿瘤医院
【出 处】
：
第十六届全国临床肿瘤学大会暨2013年CSCO学术年会
论文部分内容阅读
目的: Gefitinib has come to be the most widely used epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in treatment of advanced non-small cell lung cancer (NSCLC) in Asian patients.Common side effects of gefitinib consist of mild to moderate skin rash and diarrhea, however, drug-induced liver injury of various severities is underappreciated in long-term administered patients and rarely reported.
其他文献
Background: Afatinib is an oral, irreversible, ErbB Family Blocker, blocking signaling from EGFR (ErbB1), HER2 (ErbB2) and ErbB4.Afatinib was superior to first-line pemetrexed/cisplatin in terms of pr
目的: To investigate the roles of miR-9 and CXCR4 in laryngeal squamous cancer stem cells and regulatory mechanism.方法: MiR-9 and CXCR4 were detected in cervical lymph node metastases of laryngeal squamo
Objective: To analyze clinico-pathologic and genetic characteristics of EGFR-mutated lung cancer patients with progression from adenocarcinoma to small cell carcinoma after EGFR-TKI therapy.
Background: As one of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI),gefitinib has been proven to be highly effective for patients with advanced NSCLC.However, almost all pa
目的: It has been demonstrated that pemetrexed/cisplatin (A/C) has superior survival benefit and better safety profile over standard first line chemotherapy with gemcitabine/cisplatin (G/C) in patients
目的:阿帕替尼是靶向血管内皮生长因子受体2(VEGFR2)的口服高效小分子受体酪氨酸激酶抑制剂.Ⅰ期研究(NCT01497704)显示,推荐剂量750mg/d的阿帕替尼具有较好的耐受性和抗肿瘤疗效.本Ⅱ期、开放研究旨在评估阿帕替尼单药治疗转移性三阴性乳腺癌患者的有效性和安全性.方法:首先开展的单中心Ⅱa期研究入组了25例先前蒽环和/或紫杉类治疗过的患者.
目的:中国版NCCN乳腺癌指南推荐多西他赛联合卡培他滨(TX方案)为蒽环类失败后转移性乳腺癌的标准治疗方案,而长春瑞滨联合卡培他滨/(NX方案)可用于蒽环和紫杉类失败后的转移性乳腺癌.TX方案循证依据较强,而NX方案在国内外基本上无大型临床研究,但为临床常用且被广泛接受.国内外关于两者对比的临床研究很少,本研究比较卡培他滨联合多西他赛与卡培他滨联合长春瑞滨在晚期乳腺癌一、二线解救治疗的疗效.
目的:探讨华蟾素注射液对H22肝癌小鼠肿瘤组织中Fas、FasL基因表达的影响.方法:40只ICR小鼠采用皮下接种H22肝癌细胞株的方法复制小鼠肝癌模型,造模成功后,将小鼠随机分为4组:模型组,顺铂组,华蟾素注射液低、高剂量组.
目的:观察以奥施康定为初始滴定治疗中、重度癌痛的临床疗效.方法:有明确组织学诊断的晚期癌症患者,可准确评估疼痛强度(且NRS＞4分),PS＞2分,年龄≥18岁,既往未使用过奥施康定、盐酸吗啡片的患者随机分为治疗组和对照组,每组35例病人;治疗组:盐酸羟考酮缓释片(奥施康定)10mg,Q12hpo,应用氨酚羟考酮(泰勒宁)1-2片,prn,po处理爆发痛;对照组:应用盐酸吗啡片10mg,Q4h po
目的:探讨肺癌脑室内转移对伴发脑膜转移的提示意义.方法:回顾性分析19例存在脑室内转移的肺癌患者临床表现、影像学、脑脊液检查等相关临床资料.其中肺腺癌4例,肺小细胞癌15例.全部患者行头部磁共振平扫+增强扫描,均有脑室内转移病灶,同时伴脑实质内转移灶;16例患者脑室内病灶位于侧脑室,4例位于三脑室,8例位于四脑室及中脑导水管;其中9例同时存在脑室内2个部位转移病灶;5例混合室管膜强化;3例患者混合